Historical Valuation
Centessa Pharmaceuticals PLC (CNTA) is now in the Fair zone, suggesting that its current forward PS ratio of 4511.78 is considered Fairly compared with the five-year average of -6.24. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：22.42
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Centessa Pharmaceuticals PLC (CNTA) has a current Price-to-Book (P/B) ratio of 10.56. Compared to its 3-year average P/B ratio of 4.47 , the current P/B ratio is approximately 136.43% higher. Relative to its 5-year average P/B ratio of 4.16, the current P/B ratio is about 154.07% higher. Centessa Pharmaceuticals PLC (CNTA) has a Forward Free Cash Flow (FCF) yield of approximately -5.24%. Compared to its 3-year average FCF yield of -18.91%, the current FCF yield is approximately -72.31% lower. Relative to its 5-year average FCF yield of -21.70% , the current FCF yield is about -75.88% lower.
P/B
Median3y
4.47
Median5y
4.16
FCF Yield
Median3y
-18.91
Median5y
-21.70
Competitors Valuation Multiple
AI Analysis for CNTA
The average P/S ratio for CNTA competitors is 775.29, providing a benchmark for relative valuation. Centessa Pharmaceuticals PLC Corp (CNTA.O) exhibits a P/S ratio of 4511.78, which is 481.94% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for CNTA
1Y
3Y
5Y
Market capitalization of CNTA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CNTA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CNTA currently overvalued or undervalued?
Centessa Pharmaceuticals PLC (CNTA) is now in the Fair zone, suggesting that its current forward PS ratio of 4511.78 is considered Fairly compared with the five-year average of -6.24. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between to according to relative valuation methord.
What is Centessa Pharmaceuticals PLC (CNTA) fair value?
CNTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between to according to relative valuation methord.
How does CNTA's valuation metrics compare to the industry average?
The average P/S ratio for CNTA's competitors is 775.29, providing a benchmark for relative valuation. Centessa Pharmaceuticals PLC Corp (CNTA) exhibits a P/S ratio of 4511.78, which is 481.94% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Centessa Pharmaceuticals PLC (CNTA) as of Jan 11 2026?
As of Jan 11 2026, Centessa Pharmaceuticals PLC (CNTA) has a P/B ratio of 10.56. This indicates that the market values CNTA at 10.56 times its book value.
What is the current FCF Yield for Centessa Pharmaceuticals PLC (CNTA) as of Jan 11 2026?
As of Jan 11 2026, Centessa Pharmaceuticals PLC (CNTA) has a FCF Yield of -5.24%. This means that for every dollar of Centessa Pharmaceuticals PLC’s market capitalization, the company generates -5.24 cents in free cash flow.
What is the current Forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA) as of Jan 11 2026?
As of Jan 11 2026, Centessa Pharmaceuticals PLC (CNTA) has a Forward P/E ratio of -14.61. This means the market is willing to pay $-14.61 for every dollar of Centessa Pharmaceuticals PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Centessa Pharmaceuticals PLC (CNTA) as of Jan 11 2026?
As of Jan 11 2026, Centessa Pharmaceuticals PLC (CNTA) has a Forward P/S ratio of 4511.78. This means the market is valuing CNTA at $4511.78 for every dollar of expected revenue over the next 12 months.